Novo Nordisk Ends Wegovy Partnership with Hims Over “Deceptive Marketing” Concerns
Novo Nordisk has ended its partnership with telehealth provider Hims & Hers Health, citing concerns about deceptive marketing practices related to weight-loss drugs. The collaboration, initiated in April, enabled Hims & Hers to offer Wegovy, a branded weight management medication, at a discounted price. However, Novo Nordisk took issue with Hims & Hers’ ongoing promotion of compounded versions of semaglutide, the active ingredient in Wegovy, which are not FDA-approved and were only permitted temporarily due to a shortage that has since been resolved. Novo Nordisk emphasized its commitment to taking action against companies involved in “illegal sham compounding” that endangers public health.
John Q. Hosedrinker